论文部分内容阅读
目的:分析结核耐药试验结果的相关因素,为抗结核病药物治疗提供依据。方法:对104例临床诊断肺结核患者,在抗结核治疗前,取经液化痰液接种于酸性罗氏培养基培养分离结核分枝杆菌,然后接种于结核分枝杆菌药敏培养基进行药敏试验。结果:104例药敏试验中,结核分枝杆菌总耐药菌株为41例,总耐药率为39.4%,其中耐多药菌株34株,耐药率为32.7%。结论:结核患者已出现耐药趋势,且有向耐多药发展,而在没有出现更有效新药替代已产生耐药的药物前,必须坚持科学合理的抗结核病药物治疗原则,从而减少传染性肺结核患者的复治。
Objective: To analyze the related factors of tuberculosis drug resistance test results and provide the basis for anti-tuberculosis drug treatment. Methods: 104 patients with clinically diagnosed pulmonary tuberculosis were treated with liquefied sputum and inoculated into acidic Roche medium to culture and isolate M. tuberculosis before anti-TB treatment, and then inoculated into Mycobacterium tuberculosis susceptibility culture medium for susceptibility testing. Results: Of the 104 drug susceptibility tests, the total drug-resistant strains of Mycobacterium tuberculosis were 41 cases, the total drug-resistance rate was 39.4%, of which 34 were multidrug-resistant strains, the drug resistance rate was 32.7%. CONCLUSIONS: Tuberculosis patients have developed resistance trends and have the development of multi-drug resistance. Before there is no more effective new drug replacement drug that has become drug-resistant, it is imperative to adhere to the scientific and rational anti-tuberculosis drug treatment principle so as to reduce the incidence of infectious tuberculosis Patients with retreatment.